How should I treat mild cellulitis with oral cefalexin (Keflex) in an adult, including dosing, adjustments for renal impairment, and alternative regimens for penicillin allergy or MRSA risk?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Mild Cellulitis with Cephalexin (Keflex)

For mild, nonpurulent cellulitis in adults, treat with cephalexin 500 mg orally four times daily for 5 days, targeting streptococci as the primary pathogen. 1

Dosing Regimen

Standard Adult Dosing

  • Cephalexin 500 mg orally every 6 hours (four times daily) is the recommended dose for skin and soft tissue infections 1, 2
  • Alternative dosing: 500 mg every 12 hours is FDA-approved for uncomplicated skin infections, though QID dosing provides more consistent coverage 2
  • Duration: 5 days is as effective as 10 days if clinical improvement occurs by day 5 1

Pediatric Dosing

  • 25-50 mg/kg/day divided into 4 doses (or every 12 hours for skin infections) 1, 2
  • For streptococcal infections requiring treatment for ≥10 days, maintain therapeutic dosing throughout 2

Renal Impairment Adjustments

While the FDA label doesn't provide specific renal dosing for cephalexin 2, dose reduction is generally recommended for severe renal impairment (CrCl <30 mL/min). Consider reducing to 250-500 mg every 8-12 hours in this population, though consultation with pharmacy or nephrology may be warranted for precise adjustments.

When Cephalexin is Appropriate

Use cephalexin monotherapy when:

  • Cellulitis is nonpurulent (no drainage, exudate, or abscess) 3
  • No systemic signs of infection (no fever >38°C, tachycardia, hypotension) 1
  • No risk factors for MRSA (see below)
  • Patient can be managed as outpatient 1

The rationale: β-lactams like cephalexin were successful in 96% of cellulitis cases in a prospective study, confirming that MRSA is an uncommon cause of typical cellulitis 1. Streptococci (particularly β-hemolytic streptococci) remain the primary pathogens in nonpurulent cellulitis.

When to Add or Switch to MRSA Coverage

Do NOT use cephalexin alone if any of these MRSA risk factors are present:

  • Purulent drainage or exudate (even without drainable abscess) 3
  • Penetrating trauma, especially injection drug use 1
  • Evidence of MRSA infection elsewhere or known MRSA colonization 1
  • Failed initial β-lactam therapy 3
  • Systemic toxicity (SIRS criteria present) 1

For MRSA coverage, add or switch to:

  • Clindamycin 300-450 mg orally four times daily (covers both streptococci and MRSA) 1, 3
  • TMP-SMX 1-2 double-strength tablets twice daily PLUS cephalexin (TMP-SMX alone has poor streptococcal coverage) 1, 3
  • Doxycycline 100 mg twice daily PLUS a β-lactam (same reasoning as TMP-SMX) 1, 3

Critical pitfall: TMP-SMX and doxycycline have unreliable activity against β-hemolytic streptococci. A recent double-blind study confirmed that TMP-SMX plus cephalexin was no more effective than cephalexin alone for pure cellulitis 1, reinforcing that adding MRSA coverage to nonpurulent cellulitis without risk factors is unnecessary.

Penicillin Allergy Considerations

Cephalexin can be used in most patients reporting penicillin allergy 4:

  • Less than 5% of patients with penicillin allergy labels have true allergy 4
  • Cross-reactivity between penicillins and first-generation cephalosporins is low (1-3%) 4
  • Exception: Slightly higher cross-reactivity risk exists with amino-penicillin allergies (amoxicillin/ampicillin) due to shared R1 side chains 4

For true penicillin allergy (especially anaphylaxis to amino-penicillins):

  • Clindamycin 300-450 mg orally four times daily is the preferred alternative 1, 3
  • Doxycycline 100 mg twice daily is another option (avoid in children <8 years) 1, 3

Adjunctive Measures

Always recommend:

  • Elevation of affected limb to promote drainage of edema 1
  • Examine interdigital toe spaces for tinea pedis in lower extremity cellulitis—treating fungal infection reduces recurrence 1
  • Mark borders of erythema to monitor progression
  • Address predisposing factors (venous insufficiency, lymphedema, skin trauma) 1

When to Escalate Care

Hospitalize or consider IV therapy if:

  • SIRS criteria present (fever, tachycardia, tachypnea, leukocytosis/leukopenia) 1
  • Hemodynamic instability or altered mental status 1
  • Concern for deeper/necrotizing infection 1
  • Severe immunocompromise 1
  • Poor adherence anticipated 1

For hospitalized patients requiring IV therapy, cefazolin 1 g every 8 hours IV is appropriate for nonpurulent cellulitis, with modification to vancomycin if no clinical response 1, 3.

Monitoring and Follow-up

  • Reassess at 48-72 hours to ensure clinical improvement
  • Expect initial worsening in first 24-48 hours as bacterial lysis releases inflammatory mediators 1
  • If no improvement by 48-72 hours, consider MRSA coverage or alternative diagnosis
  • Extend therapy beyond 5 days only if infection has not improved by that timepoint 1

Evidence Quality Note

These recommendations are based on strong evidence from IDSA guidelines (2014) 1 and IDSA MRSA guidelines (2011) 3, which remain the most authoritative sources. Recent research supports higher doses (1000 mg QID) may reduce treatment failure 5, though this is not yet standard practice. Cost-effectiveness analyses confirm cephalexin remains optimal at current MRSA prevalence levels 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.